ERBB2 and neoplasm: Due to the presence of both anti-human CD3 and anti-human HER-2 derived scFv, this nanostrategy is capable of simultaneously targeting T-cell surface CD3 and cancer cell-associated HER-2 receptors, exhibiting enhanced and specific anti-tumor activity, both in vitro and in vivo, compared to SKBR-3, HCC 1954 HER-2+ and MDA-MB-468 HER-2− BC cells using an HCC 1954 xenograft tumor model [86].